SNPX $3.04 ($19.6 Million cash on balance sheet with 1.3 million float)
$19,600,000 / 1,300,000 float = $15 cash per share
They also formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors on Dec 20, 2024
NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding.